A Study of Dipeptidyl-peptidase IV (DPP-IV) RO4876904 in... | NCT00502710 | Trialant

A Study of Dipeptidyl-peptidase IV (DPP-IV) RO4876904 in... | NCT00502710 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
RO4876904 1	Experimental	Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.	Drug: RO4876904
RO4876904 2	Experimental	Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.	Drug: RO4876904
RO4876904 3	Experimental	Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.	Drug: RO4876904
RO4876904 4	Experimental	Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.	Drug: RO4876904
Placebo	Placebo Comparator	Placebo po daily. Patients receiving metformin before the study will continue on the same dose of metformin.	Drug: Placebo

Outcomes Module

Secondary Outcomes

Measure	Description	Time Frame
Absolute change in fasting plasma glucose (FPG), HbA1c response rate, absolute/relative change in insulin sensitivity, beta cell function, lipid profile.		Week 12
Adverse events (AEs), vital signs, laboratory parameters.		Throughout study

Contacts/Locations Module